- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05629689
En studie for å evaluere GEH200520/GEH200521 (18F) sikkerhet og tolerabilitet når den brukes til PET-skanning hos pasienter med solide svulster
En fase 1a/1b, multisenter, åpen etikett, dose-eskalering og dose-ekspansjonsstudie i pasienter med solide svulster for å evaluere GEH200520-injeksjon / GEH200521 (18F) Injeksjonssikkerhet og -tolerabilitet, PET-avbildning, og farmakokinetikk Bildebehandling etter behandling
Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.
Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.
Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit. Two late imaging transfer expected post follow up visit. The estimated duration for subject participation in Part B is approximately 64 days.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Amsterdam, Nederland
- Amsterdam UMC
-
Groningen, Nederland
- UMC Groningen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
- The subject is male or female, ≥18 years of age.
- Subject has a life expectancy ≥12 weeks.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Subject has an unresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma, or an unresectable stage III-IV melanoma.
- Subject is eligible for ICI treatment per Investigator judgement.
- Subject has at least 1 measurable tumour lesion documented on CT/magnetic resonance imaging (MRI) RECIST v1.1 during the last 12 months.
- Subject has a tumour lesion(s) of which a biopsy can safely be obtained according to standard clinical care procedures.
- Subject is male or female that agrees to adhere to the protocol contraception methods.
Exclusion Criteria:
- Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
- Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
- Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
- Subject has serious non-malignant disease or conditions that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has B or T cell lymphoma.
- Subject has brain or bone-marrow metastasis that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has signs or symptoms of systemic infection within 2 weeks prior to imaging day.
- Subject has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins or known allergy to the study IMP ingredients and/or the proposed ICI therapy.
- Subject has any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the ICI treatment, or that may affect the interpretation of the results or render the subject at high risk from complications.
- Subject has laboratory values out of range per protocol.
- Subject has any safety laboratory test results (blood chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has had any major surgery within 4 weeks prior to enrollment.
- Subject has been enrolled in another interventional clinical study within the 30 days before screening for this study, except for the study site IIS.
- Subject is pregnant or planning to become pregnant or is breastfeeding.
- Subject has a history of alcohol or drug abuse within the last year.
- Subject has had treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to dosing with the IMP.
- Subject has had treatment with systemic immunosuppressive medications within 2 weeks prior to dosing with the IMP.
- Subject has received acute, low-dose, systemic immunosuppressant medications that, in the opinion of the Investigator, could compromise protocol objectives.
- Subject has used systemic corticosteroids to treat inflammatory or autoimmune symptoms.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part A Cohort 1 - 1 mg dose
1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Eksperimentell: Part A Cohort 2 - 2 mg dose
2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Eksperimentell: Part A Cohort 3 - 4 mg dose
4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Eksperimentell: Part A Cohort 4 - 8 mg dose
8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Eksperimentell: Part A Cohort 5 (optional) - 12 or 15 mg dose
12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Eksperimentell: Part A Cohort 6 - Optimal dose
Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Eksperimentell: Part B
Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Del A: Forekomsten av AE etter årsakssammenheng til IMPene.
Tidsramme: Del A: 7 dager
|
Del A: 7 dager
|
|
Del A: Alvorlighetsgraden av bivirkninger i henhold til National Cancer Institutes Common Terminology Criteria for Adverse Events (NCI CTCAE versjon 5.0) etter årsakssammenheng til IMPene.
Tidsramme: Del A: 7 dager
|
Del A: 7 dager
|
|
For å evaluere tidsforløpsendringene i GEH200521 (18F) Injeksjonsopptak etter behandlingssykluser med immunsjekkpunkthemmer (ICI) sammenlignet med baseline.
Tidsramme: Del B: 50 dager
|
Del B: 50 dager
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
For å evaluere strålingsdosimetrien til en fast dose av GEH200521 (18F) Injeksjon når den administreres med de forskjellige GEH200520 Injeksjonsmassedosene etter kumulert aktivitet i kilderegioner og av hele kroppen.
Tidsramme: 7 dager
|
7 dager
|
|
|
For å evaluere det optimale tidsvinduet for bildediagnostikk for GEH200521 (18F) injeksjonspositronemisjonstomografi (PET)-avbildning når det administreres med forskjellige GEH200520-injeksjonsmassedoser for del A-personer.
Tidsramme: 7 dager
|
7 dager
|
|
|
For å bestemme riktig massedose av GEH200520-injeksjon for administrering med GEH200521 (18F)-injeksjon for å oppnå en akseptabel PET-bildekvalitet for del A-objekter.
Tidsramme: 7 dager
|
7 dager
|
|
|
For å vurdere immunogenisitet, via forekomsten av behandlingsinduserte anti-legemiddel-antistoffresponser, etter en enkelt injeksjon av de forskjellige GEH200520-injeksjonsmassedosene administrert med en fast dose av GEH200521 (18F) Injeksjon for del A-individer.
Tidsramme: 7 dager
|
7 dager
|
|
|
Innsamling av forekomst, alvorlighetsgrad, endringer mellom besøk for AE/SAE/AESI
Tidsramme: 50 dager
|
50 dager
|
|
|
For å vurdere biodistribusjonen og tumoropptaket av GEH200521 (18F) Injeksjon med den optimale GEH200520 Injeksjonsdosen bestemt i del A basert på kvantitative målinger av GEH200521 (18F) i områder av interesse for del B-personer.
Tidsramme: 50 dager
|
50 dager
|
|
|
For å vurdere forholdet mellom tumor GEH200521 (18F) Injeksjonsopptak (SUV-verdi) og immuncelle CD8+-ekspresjonsscore fra en biopsiprøve/resektert lesjon når tilgjengelig basert på IHC-resultater for del B-personer.
Tidsramme: 50 dager
|
50 dager
|
|
|
For å sammenligne endringer i tumor GEH200521 (18F) Injeksjonsopptak med endringer i computertomografi (CT) bildevurdering, i henhold til Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for Del B-emner når tilgjengelig .
Tidsramme: 50 dager
|
50 dager
|
|
|
For å sammenligne endringer i tumor GEH200521 (18F) Injeksjonsopptak med endringer i computertomografi (CT) bildevurdering, i henhold til [18F]-fluordeoksyglukose (FDG)-skanninger, når tilgjengelig for del B-emner.
Tidsramme: 50 dager
|
50 dager
|
|
|
For å sammenligne immunogenisitet, via forekomsten av behandlingsinduserte anti-legemiddel-antistoffresponser, etter flere administreringer av GEH200520-injeksjon med GEH200521 (18F)-injeksjon for del B-individer.
Tidsramme: 50 dager
|
50 dager
|
|
|
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Tidsramme: 7 days
|
The PK parameter to be assessed: AUC |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Tidsramme: 7 days
|
The PK parameter to be assessed: Cmax |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Tidsramme: 7 days
|
The PK parameter to be assessed: CL |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Tidsramme: 7 days
|
The PK parameter to be assessed: V |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Tidsramme: 7 days
|
The PK parameter to be assessed: t1/2 |
7 days
|
|
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
Tidsramme: 7 days
|
Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term |
7 days
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Tidsramme: Baseline, 24 hours, 7 days post IMP administration
|
The findings in the physical exam pre and post-administration will be summarized. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Tidsramme: Baseline, 24 hours, 7 days post IMP administration
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Tidsramme: Baseline, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Tidsramme: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Tidsramme: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Tidsramme: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Tidsramme: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Descriptive statistics will be used to describe the observed values and change from baseline. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration physical exam status values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Tidsramme: Baseline, Day 15, Day 36, Day 50
|
Descriptive statistics will be used to describe the observed values and change from baseline. |
Baseline, Day 15, Day 36, Day 50
|
|
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Tidsramme: 50 days
|
The PK parameter to be assessed: AUC |
50 days
|
|
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Tidsramme: 50 days
|
The PK parameter to be assessed: Cmax |
50 days
|
|
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Tidsramme: 50 days
|
The PK parameter to be assessed: CL |
50 days
|
|
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Tidsramme: 50 days
|
The PK parameter to be assessed: V |
50 days
|
|
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Tidsramme: 50 days
|
The PK parameter to be assessed: t1/2 |
50 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Ravi Karra, MD, GE Healthcare
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GE-269-001
- 2024-515218-42-00 (Ctis)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .